Back

Comparative performance of the concurrent comparator design with existing vaccine safety surveillance approaches on real-world observational health data

Chattopadhyay, S.; Bu, F.; Schuemie, M. J.; McLeggon, J.-A.; Westlund, E.; Hripcsak, G.; Ryan, P. B.; Suchard, M. A.

2026-01-26 public and global health
10.64898/2026.01.25.26344812 medRxiv
Show abstract

BackgroundIt is critical public health concern to identify safety signals originating from wide-scale immunization efforts. Such safety signals may be identified from spontaneous reports and other data sources. Although some work has been done on the best methods for vaccine safety surveillance, there is a scarcity of information on how these perform in analyses of real-world data. MethodsWe use four administrative claims databases and one electronic health record (EHR) database to evaluate the operating characteristics of the recently proposed concurrent comparator, self-controlled case series, historical comparator and case-control epidemiological designs for vaccine safety, using negative control outcomes (unrelated to the vaccine), imputed positive control outcomes, and one real-world positive control outcome (myocarditis or pericarditis) for COVID-19. In this evaluation, we consider vaccine exposures for COVID-19, 2017-2018 seasonal influenza, H1N1pdm flu, Human Papillomavirus (HPV), and Varicella-Zoster. The methods are compared based on type 1 error, power of association detection, and proportion of non-finite association estimates produced. ResultsAll methods exhibit systematic error, leading to type 1 errors that are greater than the nominal (= 0.05) threshold, often by a substantial amount. To restore near-nominal type 1 error, we carry out empirical calibration based on the large set of negative controls. Post-empirical calibration, the self-controlled case series designs had the highest power overall, closely followed by the concurrent comparator designs. However, concurrent comparator analyses often produced a higher proportion of non-finite estimates. ConclusionOur results indicate that there remains non-negligible systematic error under the concurrent comparator. In terms of statistical performance, the concurrent comparator designs show promising results in some scenarios, regularly outperforming the historical comparator and case-control designs, but often producing non-finite estimates. Future work building on the concurrent comparator design is required to construct more efficient designs with lower systematic error.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
BMC Medical Research Methodology
43 papers in training set
Top 0.1%
17.9%
2
Vaccine
189 papers in training set
Top 0.4%
8.2%
3
PLOS ONE
4510 papers in training set
Top 23%
8.2%
4
BMC Medicine
163 papers in training set
Top 0.4%
7.0%
5
Clinical Infectious Diseases
231 papers in training set
Top 0.9%
6.2%
6
American Journal of Epidemiology
57 papers in training set
Top 0.2%
4.8%
50% of probability mass above
7
BMJ Open
554 papers in training set
Top 5%
4.2%
8
Trials
25 papers in training set
Top 0.4%
3.9%
9
BMC Infectious Diseases
118 papers in training set
Top 2%
2.6%
10
JMIR Public Health and Surveillance
45 papers in training set
Top 1%
2.3%
11
Pharmacoepidemiology and Drug Safety
13 papers in training set
Top 0.2%
2.0%
12
International Journal of Epidemiology
74 papers in training set
Top 1%
1.7%
13
Journal of Medical Internet Research
85 papers in training set
Top 3%
1.6%
14
Frontiers in Pharmacology
100 papers in training set
Top 3%
1.5%
15
Journal of the American Medical Informatics Association
61 papers in training set
Top 1%
1.3%
16
JAMA Network Open
127 papers in training set
Top 3%
1.2%
17
Vaccines
196 papers in training set
Top 2%
1.2%
18
Scientific Reports
3102 papers in training set
Top 68%
1.1%
19
Nature Communications
4913 papers in training set
Top 59%
0.9%
20
BMC Research Notes
29 papers in training set
Top 0.4%
0.9%
21
Epidemiology and Infection
84 papers in training set
Top 3%
0.9%
22
BMC Public Health
147 papers in training set
Top 5%
0.9%
23
BMJ
49 papers in training set
Top 1%
0.8%
24
Vaccine: X
19 papers in training set
Top 0.3%
0.7%
25
PLOS Computational Biology
1633 papers in training set
Top 25%
0.7%
26
PLOS Medicine
98 papers in training set
Top 5%
0.7%
27
Research Synthesis Methods
20 papers in training set
Top 0.2%
0.7%
28
Statistics in Medicine
34 papers in training set
Top 0.4%
0.7%
29
F1000Research
79 papers in training set
Top 5%
0.7%
30
Journal of Public Health
23 papers in training set
Top 1%
0.7%